Claims for Patent: 6,566,064

Summary for Patent: 6,566,064

Title:	Method for anticipating sensitivity to medicine for osteoporosis
Abstract:	A method for anticipating sensitivity to a medicine for osteoporosis is provided which is characterized by analyzing respective genetic polymorphisms of a vitamin D receptor gene, an estrogen receptor gene, and an apolipoprotein E gene from a genome DNA contained in a sample obtained from a human, and anticipating, based on the analyzed combination of the genetic polymorphisms, that the sample is derived from an individual who shows a specific priority to sensitivities to a plurality of remedies for osteoporosis. A reagent for simultaneously detecting genetic polymorphisms is also provided which contains amplification primers and/or detection probes specific to respective genes of the vitamin D receptor gene, apolipoprotein E gene, and estrogen receptor gene. Further, a method for simultaneously detecting these genes, and a method for selecting remedies for bone disease based on the genetic polymorphisms are provided. According to the method of the present invention, a diagnosis as to which remedy, or medicine, for osteoporosis a subject patient has higher sensitivity can be made before the administration of the medicine so that selection of an appropriate medicine is possible and the QOL (quality of life) of the patient can be improved.
Inventor(s):	Shiraki; Masataka (Misato-mura, JP), Ouchi; Yasuyoshi (Tokyo-to, JP), Hosoi; Takayuki (Tokyo-to, JP), Kusaba; Nobutaka (Osaka, JP), Baba; Toshiaki (Osaka, JP), Yoshida; Hiroshi (Osaka, JP)
Assignee:	Nipro Corporation (Osaka, JP)
Application Number:	09/572,891
Patent Claims:	1. A method for determining the relative sensitivity of an individual to treatment of osteoporosis with vitamin D, estrogen, and vitamin K2, comprising determining whether an individual's vitamin D receptor genotype is B(+) or B(-), where B(+) represents the genotypes BB and Bb and B(-) represents the genotype bb, where B is a vitamin D receptor allele that is not cleaved with Bsm I in an intron region between exon 8 and exon 9 and b is a vitamin D receptor allele that is cleaved with Bsm I in an intron region between exon 8 and exon 9, determining whether the individual's estrogen receptor genotype is X(+) or X(-), where X(+) represents the genotypes XX and Xx and X(-) represents the genotype xx, where X is an estrogen receptor allele that is not cleaved with Xba in an intron region between exon 1 and exon 2 and x is an estrogen receptor allele that is cleaved with Xba in an intron region between exon 1 and exon 2, and determining whether the individual's apolipoprotein E genotype is 3(+), 3(-), 4(+), or 4(-), where 3(+) represents an apolipoprotein E 3/3 type, and 3(-) indicates an apolipoprotein E genotype other than apolipoprotein E 3/3 type, and 4 represents an apolipoprotein E4 allele, and (+) and (-) indicate the presence and absence, respectively, of the allele; wherein the combination of said individual's vitamin D receptor genotype, estrogen receptor genotype, and apolipoprotein E genotype is associated with the individual's relative sensitivity to vitamin D, estrogen and vitamin K2.

Details for Patent 6,566,064

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2019-05-18
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2019-05-18
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2019-05-18